Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Investigational Tdap vaccine Formulation B
- Development stage
- Preclinical
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Investigational Tdap vaccine Formulation B is a Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Adsorbed (Tdap) vaccine developed by Sanofi Pasteur. It is administered as a suspension for intramuscular injection. The vaccine is designed to induce humoral and cell-mediated immune responses to protect against Tetanus, Diphtheria, and Pertussis.
- Other names
- investigational Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Adsorbed (Tdap) vaccine formulation B
02
Targets
FIM2/FIM3 (Fimbriae types 2 and 3)TT (Tetanus toxoid)
Beyond the preview
Go deeper on Investigational Tdap vaccine Formulation B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Investigational Tdap vaccine Formulation B.